Activation of MyoD-dependent Transcription by Cdk9/cyclin T2
Overview
Authors
Affiliations
Myogenic transcription is repressed in myoblasts by serum-activated cyclin-dependent kinases, such as cdk2 and cdk4. Serum withdrawal promotes muscle-specific gene expression at least in part by down-regulating the activity of these cdks. Unlike the other cdks, cdk9 is not serum- or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase II. While ectopic expression of cdk2 together with its regulatory subunits (cyclins E and A) inhibits myogenic transcription, overproduction of cdk9 and its associated cyclin (cyclin T2a) strengthens MyoD-dependent transcription and stimulates myogenic differentiation in both MyoD-converted fibroblasts and C2C12 muscle cells. Conversely, inhibition of cdk9 activity by a dominant negative form (cdk9-dn) represses the myogenic program. Cdk9, cyclinT2 and MyoD can be detected in a multimeric complex in C2C12 cells, with the minimal cdk9-binding region of MyoD mapping within 101-161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of muscle differentiation includes the direct enzymatic activity of the kinase on MyoD.
Battistelli C, Garbo S, Maione R Cells. 2022; 11(21).
PMID: 36359831 PMC: 9654159. DOI: 10.3390/cells11213435.
Revealing phosphorylation regulatory networks during embryogenesis of honey bee worker and drone ().
Ma B, Ma C, Li J, Fang Y Front Cell Dev Biol. 2022; 10:1006964.
PMID: 36225314 PMC: 9548569. DOI: 10.3389/fcell.2022.1006964.
Zhang C, Zhao J, Guo Y, Xu Q, Liu M, Cheng M Front Vet Sci. 2022; 9:909039.
PMID: 35847642 PMC: 9280686. DOI: 10.3389/fvets.2022.909039.
Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex.
Funamoto M, Sunagawa Y, Gempei M, Shimizu K, Katanasaka Y, Shimizu S Pharmaceutics. 2022; 14(6).
PMID: 35745840 PMC: 9227296. DOI: 10.3390/pharmaceutics14061269.
The Prognostic Role of CDK9 in Bladder Cancer.
Borowczak J, Szczerbowski K, Maniewski M, Zdrenka M, Slupski P, Antosik P Cancers (Basel). 2022; 14(6).
PMID: 35326643 PMC: 8945910. DOI: 10.3390/cancers14061492.